Methotrexate for treating XXXX .

@entity1 @entity32 @entity625 @entity353 @entity4 @entity4932 @entity1500 @entity158 @entity309
BACKGROUND: In both adult @entity309 ( @entity309 ) and @entity625 , the focus has shifted from ' @entity32 parameters' to more @entity1 centered disability outcomes. In @entity309 this resulted in the development of the Outcome Measures in Arthritis Clinical Trials (OMERACT), and in @entity625 the Pediatric Rheumatology International Trials Organization (PRINTO) core set. This PRINTO-core set was established using a combination of statistical and consensus formation techniques. This core set contains a number of @entity1 centered disability measures. This review systematically searched the available literature and reports the available evidence of efficacy of @entity1500 , with special focus on @entity1 centered disability measures in @entity4932 ( @entity4932 ). OBJECTIVES: To perform a systematic review on the effects of @entity1500 on functional ability, range of motion, quality of life, overall well-being and @entity158 for @entity1 with @entity4932 . SEARCH STRATEGY: The Cochrane Controlled Trials Register (CCTR) and MEDLINE were searched up to March 2001, using the search strategy sensitive for randomised controlled trials, used by the Cochrane Collaboration. SELECTION CRITERIA: Randomized controlled trials and controlled clinical trials comparing @entity1500 against placebo or standard care in @entity1 with @entity4932 ( @entity4932 ) were selected. DATA COLLECTION AND ANALYSIS: Two reviewers (TT, JN) determined the studies to be included in this review and extracted the data of @entity1 centered disability measures. The data were pooled using standardized mean differences (SMD) for limited joint range score, number of joints with @entity4 . The number of joints with @entity158 on motion were evaluated using @entity353 ( @entity353 ). Physicians global assessment, parents global assessment and withdrawals due to efficacy and side effects were evaluated with pooled odds ratios (OR). MAIN RESULTS: Only two studies with a total 165 @entity4932 @entity1 under 18 years of age were included in this review. For @entity4932 @entity1 , @entity1500 therapy had small to moderate effects on @entity1 centered disability outcomes. The effect on joint range of motion, number of joints with @entity158 and @entity4 and physician's and parent's assessment of disease activity showed a relative percentage improvement from 3 to 23% greater with @entity1500 than with placebo. REVIEWER'S CONCLUSIONS: Current evidence suggests that @entity1500 does have minimal clinically significant effects (>20%) on @entity1 centered disability measures in @entity4932 @entity1 .
